Lavipharm Sa Stock Earnings Per Share
| LAVI Stock | EUR 0.71 0.01 1.39% |
Lavipharm SA fundamentals help investors to digest information that contributes to Lavipharm's financial success or failures. It also enables traders to predict the movement of Lavipharm Stock. The fundamental analysis module provides a way to measure Lavipharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lavipharm stock.
Lavipharm |
Lavipharm SA Company Earnings Per Share Analysis
Lavipharm's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Lavipharm Earnings Per Share | 0.04 X |
Most of Lavipharm's fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lavipharm SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
According to the company disclosure, Lavipharm SA has an Earnings Per Share of 0.042 times. This is 99.5% lower than that of the Healthcare sector and 99.76% lower than that of the Drug Manufacturers - Major industry. The earnings per share for all Greece stocks is 98.65% higher than that of the company.
Lavipharm Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lavipharm's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lavipharm could also be used in its relative valuation, which is a method of valuing Lavipharm by comparing valuation metrics of similar companies.Lavipharm is currently under evaluation in earnings per share category among its peers.
Lavipharm Fundamentals
| Return On Asset | 0.0403 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.08 % | |||
| Current Valuation | 59.98 M | |||
| Shares Outstanding | 18.29 M | |||
| Shares Owned By Insiders | 67.47 % | |||
| Price To Earning | 12.42 X | |||
| Price To Sales | 0.17 X | |||
| Revenue | 41.37 M | |||
| Gross Profit | 15.89 M | |||
| EBITDA | 4.72 M | |||
| Net Income | 1.72 M | |||
| Cash And Equivalents | 1.85 M | |||
| Cash Per Share | 0.04 X | |||
| Total Debt | 40.54 M | |||
| Current Ratio | 1.29 X | |||
| Book Value Per Share | (0.47) X | |||
| Cash Flow From Operations | 3.82 M | |||
| Earnings Per Share | 0.04 X | |||
| Beta | 0.66 | |||
| Market Capitalization | 8.56 M | |||
| Total Asset | 82 M | |||
| Retained Earnings | (181 M) | |||
| Working Capital | (66 M) | |||
| Current Asset | 21 M | |||
| Current Liabilities | 87 M | |||
| Z Score | -2.8 | |||
| Five Year Return | 4.13 % |
About Lavipharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lavipharm SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lavipharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lavipharm SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Lavipharm Stock Analysis
When running Lavipharm's price analysis, check to measure Lavipharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lavipharm is operating at the current time. Most of Lavipharm's value examination focuses on studying past and present price action to predict the probability of Lavipharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lavipharm's price. Additionally, you may evaluate how the addition of Lavipharm to your portfolios can decrease your overall portfolio volatility.